Kidney Transplant
Conditions
Brief summary
Varicella zoster virus is part of the herpesvirus group and causes chickenpox in exposed individuals. The majority of the population is seropositive for this virus. Reactivation of varicella zoster virus occurs in up to 30% of the general population over 60 years old. Solid organ transplant recipients receive lifelong immunosuppression drugs and are at great risk of reactivation of all herpesviruses including the varicella zoster virus regardless of age. The vaccine has been shown to be effective in preventing shingles in the general population. The investigators' purpose is to determine how well the vaccine works in patients on renal replacement therapy and post-transplant.
Interventions
BIOLOGICALZostavax (Live attenuated herpes zoster vaccine)
0.6 mL subcutaneous
BIOLOGICALPlacebo vaccine
0.65 mL subcutaneous
Sponsors
University of Alberta
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-65 years 2. Listed or will likely be listed for live donor kidney transplant within one month
Exclusion criteria
1\. Previous receipt of Zostavax
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunogenicity | 6 months |
Countries
Canada
Outcome results
None listed